Moleculin Biotech, Inc. Proceeds from Notes Payable
Moleculin Biotech, Inc. (MBRX) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2018-03-28
- Moleculin Biotech, Inc. proceeds from notes payable for the quarter ending 2017-12-31 was $0.00.
- Moleculin Biotech, Inc. proceeds from notes payable for the quarter ending 2017-09-30 was $0.00.
- Moleculin Biotech, Inc. proceeds from notes payable for the quarter ending 2017-06-30 was $0.00.
- Moleculin Biotech, Inc. proceeds from notes payable for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- Moleculin Biotech, Inc. proceeds from notes payable for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- Moleculin Biotech, Inc. proceeds from notes payable for fiscal 2016 was $165.00K.
| Period end | Proceeds from Notes Payable 2 month | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 5 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | $0.00 derived: sum of 2 quarters · filed 2018-03-28 | $0.00 derived: sum of 3 quarters · filed 2018-03-28 | $0.00 10-K · filed 2018-03-28 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $0.00 derived: sum of 2 quarters · filed 2017-11-13 | $0.00 10-Q · filed 2017-11-13 | $0.00 derived: sum of 4 quarters · filed 2018-03-28 | ||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $0.00 10-Q · filed 2017-08-11 | $0.00 derived: sum of 3 quarters · filed 2018-03-28 | $0.00 derived: sum of 4 quarters · filed 2018-03-28 | ||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-12 | $0.00 derived: sum of 2 quarters · filed 2018-03-28 | $0.00 derived: sum of 3 quarters · filed 2018-03-28 | $0.00 derived: sum of 4 quarters · filed 2018-03-28 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | $0.00 derived: sum of 2 quarters · filed 2018-03-28 | $0.00 derived: sum of 3 quarters · filed 2018-03-28 | $165.00K 10-K · filed 2018-03-28 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $0.00 derived: sum of 2 quarters · filed 2017-11-13 | $165.00K 10-Q · filed 2017-11-13 | |||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $165.00K 10-Q · filed 2017-08-11 | ||||
| 2016-03-31 | $165.00K 10-Q · filed 2017-05-12 | |||||
| 2015-12-31 | $450.00K 10-K · filed 2017-04-03 | |||||
| 2015-09-30 | $250.00K 10-Q · filed 2016-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |